See Graham's ranking
4.0
Amgen Inc. operates within the healthcare sector, specifically in the biotechnology subsector, with its shares traded on the Nasdaq under the ticker AMGN. The corporate formation is associated with William K. Bowes Jr. and a group of scientists and investors who established the company with the objective of developing biological therapies based on genetic engineering.
The product and service portfolio includes biotechnology medicines aimed at treating chronic and complex diseases, including therapies for oncology, nephrology, inflammation, cardiovascular disorders, bone metabolism and immunology. Activities encompass research, development, manufacturing and commercialization of biological molecules and biosimilar medicines.
The company’s market presence is global, with operations in the United States, Europe, Asia-Pacific and Latin America. Its operations serve healthcare systems, hospitals, specialty clinics, distributors and organizations that integrate biological and pharmaceutical supply chains.
Relevant market factors include rising demand for innovative therapies, competition with major biopharmaceutical companies, the entry of biosimilars, regulatory developments and technological advancements in genetic engineering platforms. Industry dynamics are influenced by research cycles, patents, clinical agreements and international regulatory requirements.
Operational scale involves tens of thousands of employees, industrial units dedicated to biological manufacturing, research laboratories and clinical development centers distributed across multiple countries. Commercial reach includes consolidated portfolios in several therapeutic areas and a broad global distribution network.
Operational structure includes headquarters in Thousand Oaks, California, manufacturing facilities in the United States, Puerto Rico, Ireland and the Netherlands, biomedical research centers, divisions focused on oncology and immunology therapies and units specialized in large-scale biological production. Logistics involve integrated cold-chain storage, temperature control and global distribution systems.
The operating model combines advanced internal research, scientific partnerships, clinical development and licensing agreements. Commercial activities are supported by regional teams, integration with healthcare systems and industrial capacity geared toward the continuous production of biotechnology therapies. The principal trading ticker is AMGN, listed on the Nasdaq.
History and foundation
The company was founded in 1980 in Thousand Oaks, California, initially under the name Applied Molecular Genetics, with a focus on developing technologies based on recombinant DNA. The original motivation was tied to applying genetic engineering to create novel biological therapies.
In the early years, challenges included building laboratory capabilities, securing investment and establishing viable clinical pipelines. Initial achievements included research breakthroughs that led to the development of pioneering biological medicines for severe diseases.
Expansion and growth resulted from the strengthening of scientific capabilities, entry into new therapeutic segments, development of biotechnology platforms and internationalization of operations. The portfolio was diversified through innovative therapies and geographic expansion in strategic markets.
Historical milestones include the initial public offering (IPO) completed in 1983, which enabled greater investment in research, the launch of innovative biotechnology therapies throughout the 1990s and 2000s and strategic acquisitions that strengthened the company’s position in biosimilars and oncology. Global partnerships and mergers further consolidated its presence in the biopharmaceutical sector.
Between 2020 and 2024, relevant factors included the acquisition of strategic assets, expansion of the biosimilars portfolio, investment in genetic engineering platforms, growth of international clinical trials and regulatory adjustments across global markets. Pandemic-related events, supply chain disruptions and technological advancements influenced operational performance and capital-market dynamics.
Additional Information
The Company Amgen Inc. (United States), is listed on Nasdaq with a market value of $ 176.27 Billions, having an equity of $ 9.62 Billions.
With a total of 19.200 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 35.97 Billions, which generated a profit in the amount of $ 7.01 Billions.
As for its main indicators, the Company has a P/E ratio of 25.16, a P/BV ratio of 18.33 and in the last 12 months the dividend yield of AMGN was at 2.91%.
The Company is traded internationally through the ticker AMGN.
